Revenue segments as reported by the company.

Women’s Health

Biosimilars

Established Brands

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Acquired in-process research and development and milestones

Interest expense

Exchange losses (gains)

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Organon & Co

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Organon & Co reports strong Q4 earnings, eyes growth opportunities

Organon & Co's Q4 2022 earnings call highlighted robust financial performance, strategic initiatives in key segments, and a positive outlook for future growth. Despite challenges in China and market dynamics, the company remains focused on leveraging its strengths, addressing challenges, and capitalizing on growth opportunities to drive shareholder value and portfolio expansion.

Organon & Co reports solid Q1 performance and eyes growth opportunities

Organon & Co's Q1 2023 performance reflects revenue growth, margin improvement, and strategic investments in key franchises and medical devices.
The company's strengths lie in financial discipline, strong segment performance, and growth opportunities in fertility markets and biosimilars.
Challenges include inflationary pressures, competitive pricing scenarios, and the need to address loss of exclusivity and pricing dynamics.
Opportunities exist in expanding market presence in Asia Pacific, launching new products, and focusing on sustainable growth through financial prudence.

Organon & Co reports solid Q2 earnings, eyes growth opportunities

Organon & Co's Q2 2023 performance showed revenue growth, margin improvement, and strategic focus on key business segments.
Strengths in product differentiation, market positioning, and growth drivers position the company for continued success.
Challenges in revenue drivers, market expansion, and financial strategy require strategic adjustments for sustained growth.
Opportunities in Women's Health, biosimilar portfolio, and market penetration strategies offer avenues for future growth and market leadership.

Organon reports mixed Q3 results, eyes biosimilar growth opportunities

Organon's Q3 performance showed mixed results with challenges in women's health and biosimilar uptake, but stable growth in established brands.
The company is focusing on cost efficiency, portfolio optimization, and market expansion in biosimilars for future revenue growth.
Despite near-term challenges, Organon remains optimistic about its financial outlook, especially with opportunities in biosimilars and market expansion strategies.
Strategic shifts towards retail sector in China and product optimization are key focus areas for sustained growth and profitability.

Organon & Co reports solid Q4 earnings, eyes strategic growth

Organon's Q4 2023 earnings call showcased strong financials, strategic partnerships, and a focus on cost management. The company aims for low single-digit revenue growth in 2024 and $1 billion in free cash flow.

Organon & Co reports strong Q1 performance, eyes biosimilar growth

Organon & Co's Q1 2024 showcased robust revenue growth and strategic financial planning
Challenges include flat global fertility business and cautious outlook due to foreign exchange dynamics
Opportunities lie in expanding biosimilar market, margin expansion, and transformative deals

Organon & Co reports solid Q2 earnings, eyes franchise growth

Organon & Co's Q2 2024 performance reflects a mix of solid revenue growth and margin stability.
While facing challenges in certain regions and franchise segments, the company maintains a focus on growth.
Strategic opportunities lie in expanding key franchises, regulatory milestones, and operational efficiency.
Overall, Organon & Co remains optimistic about sustained revenue growth and financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN) today announced the launch of a new website – Fertility Journey – that helps inform and empower people with resources and information needed to navigate the process of fertility care. The website aims to meet people wherever they are on their fertility journey and equip them with knowledge and questions for consideration to feel prepared and empowered throughout their journey. “Infertility is a significant public health issue in the U.S. W

Organon Launches New Fertility Journey Website as Part of Ongoing Commitment to Help Address the Needs of Women

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon Receives FDA Clearance for Technological Updates to the Jada® System, a Medical Device Intended to Control Postpartum Hemorrhage

Organon Receives FDA Clearance for Technological Updates to the Jada® System, a Medical Device Intended to Control Postpartum Hemorrhage

Organon is a new company listed on June after the spin-off from Merck. Spin-off companies tend to outperform the broad market.

Organon Is Merck's Spin-Off And Your New Dividend Prospect

Kraft Heinz

Dislocations between price and value remind me that it's a market for stocks rather than the stock market. I highlight 2 names that are trading in deep value territory and are set up for potentially strong gains.

Build Your Dividend Factory: 2 Irresistible Bargains

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon issues Public Service Announcement inviting women to ignite a global conversation on unplanned pregnancy.

Organon Aims to Ignite Worldwide Conversation Around Unplanned Pregnancy

Organon Is An Irresistible Bargain, Here's Why

Organon & Co (NYSE:OGN), which has recently spun-off from Merck & Co., Inc. (NYSE:MRK), has “inherited a global business across three segments,” namely Women's Health, Legacy and Biosimilars brands, according to BofA Securities. The Organon Analyst: Jason Gerberry initiated coverage of Organon with a Buy rating and a price target of $43.

3 Reasons To Buy Organon Stock, Says BofA Analyst

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at Morgan Stanley's 19th Annual Global Healthcare Virtual Conference on Monday, September 13, 2021 at 9:30 a.m. EDT. Investors, analysts, members of the media and the general public are invited to watch a live video webcast of the presentation at https://www.organon.com/investor-relations/eve

Organon To Present at Morgan Stanley's 19th Annual Global Healthcare Virtual Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at Citi's 16th Annual BioPharma Virtual Conference on Friday, September 10, 2021 at 9:45 a.m. EDT. Investors, analysts, members of the media and the general public are invited to watch a live video webcast of the presentation at https://www.organon.com/investor-relations/events-and-presentati

Organon To Present at Citi's 16th Annual BioPharma Virtual Conference

SAN FRANCISCO--(BUSINESS WIRE)-- #femalefounders--Avestria Ventures closes Fund I. The Bay Area-based venture capital firm invests in women's health and female-led life science ventures.

Avestria Ventures Closes Fund I

Auxier Asset Management leader Jeff Auxier (Trades, Portfolio) released his second-quarter portfolio last week.

Jeff Auxier Discloses Position in Organon, Curbs Several Top Holdings

Amazon

Bristol-Myers

BorgWarner

The S&P 500 is potentially on track for the greatest year in market history and is 30% historically overvalued.

4 Incredible Blue-Chip Bargains You Won't Want To Miss

Kroger

Merck

These were Berkshire Hathaway's biggest buys during Q2, 2021.

Top Stocks Warren Buffett Just Bought

AbbVie

Axalta Coating Systems

Biogen

Chevron

General Motors

Liberty Global Ltd

Marsh & McLennan

U.S. Bancorp

Berkshire Hathaway CEO Warren Buffett and his team were bears yet again in Q2 2021, hacking away at a large number of positions while only adding to a handful.

11 Stocks Warren Buffett Is Selling (And 3 He's Buying)

Warren Buffett (Trades, Portfolio)'s multibillion-dollar conglomerate, Berkshire Hathaway Inc. ( BRK.A , Financial)( BRK.B , Financial), disclosed its equity portfolio for the second quarter of 2021 on Monday.

Warren Buffett Welcomes Organon, Boosts Kroger in 2nd Quarter

Berkshire Hathaway's latest 13F filing revealed Warren Buffett sold plenty of stocks in Q2 2021, but added to his Kroger position and gained a "new" stake in Merck spin-off Organon.

Buffett Adds More Kroger, Welcomes Organon in Q2

On its Q2 earnings report, Organon hit all the milestones needed to move the stock out of its post-spin doldrums.

Organon: Q2 Earnings Should Alleviate Bear Concerns

Total revenue of $1.6 billion grew by a modest 4.5% YOY (-1% excluding foreign currency impact or excl.fx) reflecting the impact of loss of exclusivity on some products, but beat consensus by 5.2%.

Organon Stock Jumps On Profit Beat In First Post-Spinoff Report

Activision Blizzard

Alibaba

Chegg

B. Riley Financial

The stock market is near all-time highs, but train-wreck season lies just around the corner.

If you're nervous about the stock market at record highs, consider these five companies that are loved by the smart money

BGC Partners

Goldman Sachs

Lincoln National

Mercer International

Benjamin Graham is known for developing a fairly complex set of rules and formulas to determine a stock's intrinsic value. In his final year, Graham offered a much simpler means of finding value, but these simple value comparison tools are often overlooked by many investors.

Value Stock Selections: A Simpler Benjamin Graham

Organon's (OGN) CEO Kevin Ali on Q2 2021 Results - Earnings Call Transcript

Organon's (OGN) earnings and revenues beat estimates in the second quarter of 2021. Stock up in pre-market trading.

Organon's (OGN) Q2 Earnings & Revenues Surpass Estimates

Shares of Organon & Co. OGN, +8.00% shot up 7.1% in morning trading Thursday, after the pharmaceutical company and recent spinoff from Merck & Co. Inc. MRK, +0.38% reported second-quarter profit and revenue that beat expectations, amid strength in its women's health business, and initiated a dividend that implied a yield that was well above its peer group. Net income fell to $427 million, or $1.68 a share, from $542 million, or $2.14 a share, in the year-ago period.

Organon stock jumps after earnings beat, initiating dividend with yield well above its peer group

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN) (the “company”), today announced its results for the second quarter and year to date ended June 30, 2021 and affirmed its full year 2021 financial guidance. Organon also announced that its Board of Directors declared a quarterly dividend of $0.28 for each issued and outstanding share of the company's common stock. The dividend is payable on September 13, 2021 to stockholders of record at the close of business on August 23, 2021. "Since wel

Organon Reports Results for the Second Quarter Ended June 30, 2021 and Announces Inaugural Dividend

ObsEva

JERSEY CITY, N.J. & GENEVA, Switzerland--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), a global women's health company and ObsEva (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company dedicated to improving women's reproductive health, today announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022). Ebopiprant is an investigational, orally active, selective prostaglandin F2α (PGF2α) recep

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

News for Organon & Co Stock (OGN)